J&J signs stem cell type 1 diabetes deal with ViaCyte – PharmaTimes
|
J&J signs stem cell type 1 diabetes deal with ViaCyte
PharmaTimes Johnson & Johnson has linked up with ViaCyte with a view to getting rights to the stem cell specialist's investigational treatment for type 1 diabetes. A deal has been inked giving J&J's Janssen unit “a future right to evaluate a transaction” related … |
